Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Department of Gastroenterology and Hepatology, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
Clin J Gastroenterol. 2023 Aug;16(4):610-614. doi: 10.1007/s12328-023-01793-y. Epub 2023 Apr 15.
A 56-year-old man presented to our hospital for close examination of a mass in the portal vein. CT showed a homogeneously enhanced mass occupying the portal vein. No other lesions suggestive of a primary tumor were detected. Endoscopic ultrasound-guided fine-needle aspiration revealed that the tumor was pathologically acinar cell carcinoma (ACC) based on the positive staining for both BCL-10 and trypsin. He was diagnosed with an ectopic ACC developed in the portal vein. Because the tumor invaded secondary branches of the right intrahepatic portal vein and the superior mesenteric vein, it was considered surgically un-resectable. Therefore, chemotherapy with gemcitabine plus nab-paclitaxel (GEM + nab-PTX) was started. After 2 courses, CT showed progressive disease, so the regimen was switched to FOLFIRINOX. After starting treatment with FOLFIRINOX, the tumor shrank gradually. After 29 courses, CT scan eventually showed disappearance of the tumor and complete response was achieved. After 34 courses, the chemotherapy was discontinued. Since then, the patient has been recurrence-free for 5 years. Our English literature review yielded 6 cases, including this case, of un-resectable ACC in which complete response was achieved by chemotherapy. Our case suggest that platinum-based regimen might be an effective therapy for un-resectable ACC, including ectopic ACC.
一位 56 岁男性因门静脉内肿块到我院就诊。CT 显示门静脉内均匀强化肿块。未发现其他提示原发性肿瘤的病变。内镜超声引导下细针抽吸显示肿瘤为胰腺细胞腺癌(ACC),BCL-10 和胰蛋白酶均为阳性染色。他被诊断为发生在门静脉的异位 ACC。由于肿瘤侵犯了右肝内门静脉的次级分支和肠系膜上静脉,因此认为手术无法切除。因此,开始用吉西他滨加 nab-紫杉醇(GEM+nab-PTX)进行化疗。2 个疗程后,CT 显示病情进展,因此方案改为 FOLFIRINOX。开始使用 FOLFIRINOX 治疗后,肿瘤逐渐缩小。29 个疗程后,CT 扫描最终显示肿瘤消失,达到完全缓解。34 个疗程后,停止化疗。此后,患者无复发生存 5 年。我们的英文文献复习包括 6 例病例,包括本例不可切除的 ACC,化疗后达到完全缓解。我们的病例提示,含铂方案可能是不可切除的 ACC(包括异位 ACC)的有效治疗方法。